H.C. Wainwright analyst Matthew Caufield moved its rating on Aldeyra Therapeutics to Under Review after the company received late-cycle review minutes from the FDA related to the application for reproxalap in the topical treatment of signs and symptoms of dry eye disease.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALDX:
